Clearmind Medicine’s Reverse Stock Split And Nasdaq Delisting Notice
Clearmind Medicine Inc. (NASDAQ: CMND) is set to conduct a 1-for-30 reverse share split of its issued and outstanding ordin
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS) for Treatment-Resistant Depression and Awakn Life Sciences (OTCMKTS: AWKNF) for Severe Alcohol Use Disorder (SAUD).
Cybin Reports Access To $101M To Sustain Deuterated Psychedelics Programs, Q2 Numbers & 2024 Goals
Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) released its financial results for second quarter ended September 30, 2023.
GH Research: Steady Expenses And $229M Cash Position For 2026 Runway
The clinical-stage psychedelics biotech GH Research PLC (NASDAQ: GHRS) reported its financial results for Q3 2023 ended September 30, showing:
Enveric Biosciences’ Revenue Drops In Q3 2023 As Next-Gen Psychedelics Advance To Clinical Trials
Enveric Biosciences (NASDAQ: ENVB), a biopharma company developing novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, reported its financials for Q3 2023 ended September 30, 2023, showing:
Atai Life Sciences’ Q3 Earnings: Near $20M Burned QoQ, Says Funding ‘Sufficient’ To Streamline 2026
Clinical-stage psychedelics company atai Life Sciences (NASDAQ: ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023.
In numbers:
Psyched: Veterans & Psychedelics, $100M IPO, Cybin’s $64M Offering, Worldwide Events & More
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans?
Cybin Launches Five-Day Units Offering For Up To $64M, Suspends Prior LPC Funding Deal
Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) has announced a new underwritten offering of 66.66 million units to one of its largest institutional shareholders as well as new institutional investors.
Canada To Australia: New MDMA & Psilocybin Shipment On Its Way For Legal Therapeutic Market
The first of several of PharmAla Biotech’s (OTC: PMBHF) shipments of psychedelic molecules -both API and finished drug product capsules- to its Australian JV Cortexa for use under the Authorized Prescriber Scheme (
Psyched: DEA’s Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court